Literature DB >> 26118257

[VALIDATION OF THE HUNGARIAN MDS-UPDRS: WHY DO WE NEED A NEW PARKINSON SCALE?].

Krisztina Horvath, Péter Acs, Edit Bosnyák, Gabriella Deli, Endre Pál, Ildikó Késmárki, Katalin Takács, Sámuel Komoly, Magdolna Bokor, Eszter Rigó, Júlia Lajtos, Péter Klivényi, György Dibó, László Vécsei, Annamária Takáts, Adrián Tóth, Piroska Imre, Ferenc Nagy, Mihály Herceg, Eszter Hidasi, Norbert Kovács.   

Abstract

BACKGROUND: The Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) has been published in 2008 as the successor of the original UPDRS. The MDS-UPDRS organizing team developed guidelines for the development of official non-English translations consisting of four steps: translation/back-translation, cognitive pretesting, large field testing, and clinimetric analysis. The aim of this paper was to introduce the new MDS-UPDRS and its validation process into Hungarian.
METHODS: Two independent groups of neurologists translated the text of the MDS-UPDRS into Hungarian and subsequently back-translated into English. After the review of the back-translated English version by the MDS-UPDRS translation administration team, cognitive pretesting was conducted with ten patients. Based on the results of the initial cognitive pretesting, another round was conducted. For the large field testing phase, the Hungarian official working draft version of MDS-UPDRS was tested with 357 patients with Parkinson's disease (PD). Confirmatory factor analyses (CFA) determined whether the factor structure for the English-language MDS-UPDRS could be confirmed in data collected using the Hungarian Official Draft Version. To become an official translation, the Comparative Fit Index (CFI) had to be ≥ 0.90 compared to the English-language version.
RESULTS: For all four parts of the Hungarian MDS-UPDRS, the CFI was ≥ 0.94.
CONCLUSION: The overall factor structure of the Hungarian version was consistent with that of the English version based on the high CFIs for all the four parts of the MDS-UPDRS in the CFA; therefore, this version was designated as the "OFFICIAL GUNGARIAN VERSION OF THE MDS-UPDRS'.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 26118257

Source DB:  PubMed          Journal:  Ideggyogy Sz        ISSN: 0019-1442            Impact factor:   0.427


  11 in total

1.  Screening Mild and Major Neurocognitive Disorders in Parkinson's Disease.

Authors:  Tivadar Lucza; Kázmér Karádi; János Kállai; Rita Weintraut; József Janszky; Attila Makkos; Sámuel Komoly; Norbert Kovács
Journal:  Behav Neurol       Date:  2015-05-19       Impact factor: 3.342

2.  Is the MDS-UPDRS a Good Screening Tool for Detecting Sleep Problems and Daytime Sleepiness in Parkinson's Disease?

Authors:  Krisztina Horváth; Zsuzsanna Aschermann; Péter Acs; Edit Bosnyák; Gabriella Deli; Endre Pál; József Janszky; Béla Faludi; Ildikó Késmárki; Sámuel Komoly; Magdolna Bokor; Eszter Rigó; Júlia Lajtos; Péter Klivényi; György Dibó; László Vécsei; Annamária Takáts; Adrián Tóth; Piroska Imre; Ferenc Nagy; Mihály Herceg; Anita Kamondi; Eszter Hidasi; Norbert Kovács
Journal:  Parkinsons Dis       Date:  2014-11-17

3.  Prevalence of Anxiety among Hungarian Subjects with Parkinson's Disease.

Authors:  Márton Kovács; Attila Makkos; Rita Weintraut; Kázmér Karádi; József Janszky; Norbert Kovács
Journal:  Behav Neurol       Date:  2017-09-26       Impact factor: 3.342

4.  The Impact of Trimetazidine on Disease Severity and Quality of Life in Parkinson's Disease.

Authors:  Dávid Pintér; Annamária Juhász; Márk Harmat; József Janszky; Norbert Kovács
Journal:  Sci Rep       Date:  2020-06-22       Impact factor: 4.379

5.  Screening for Problematic Internet Use May Help Identify Impulse Control Disorders in Parkinson's Disease.

Authors:  Márton Kovács; Attila Makkos; Dávid Pintér; Annamária Juhász; Gergely Darnai; Kázmér Karádi; József Janszky; Norbert Kovács
Journal:  Behav Neurol       Date:  2019-02-03       Impact factor: 3.342

6.  Differences in MDS-UPDRS Scores Based on Hoehn and Yahr Stage and Disease Duration.

Authors:  Matej Skorvanek; Pablo Martinez-Martin; Norbert Kovacs; Mayela Rodriguez-Violante; Jean-Christophe Corvol; Pille Taba; Klaus Seppi; Oleg Levin; Anette Schrag; Thomas Foltynie; Mario Alvarez-Sanchez; Tomoko Arakaki; Zsuzsanna Aschermann; Iciar Aviles-Olmos; Eve Benchetrit; Charline Benoit; Alberto Bergareche-Yarza; Amin Cervantes-Arriaga; Anabel Chade; Florence Cormier; Veronika Datieva; David A Gallagher; Nelida Garretto; Zuzana Gdovinova; Oscar Gershanik; Milan Grofik; Vladimir Han; Jing Huang; Liis Kadastik-Eerme; Monica M Kurtis; Graziella Mangone; Juan Carlos Martinez-Castrillo; Amelia Mendoza-Rodriguez; Michal Minar; Henry P Moore; Mari Muldmaa; Christoph Mueller; Bernadette Pinter; Werner Poewe; Karin Rallmann; Eva Reiter; Carmen Rodriguez-Blazquez; Carlos Singer; Barbara C Tilley; Peter Valkovic; Christopher G Goetz; Glenn T Stebbins
Journal:  Mov Disord Clin Pract       Date:  2017-03-11

7.  Impact of Sex on the Nonmotor Symptoms and the Health-Related Quality of Life in Parkinson's Disease.

Authors:  Márton Kovács; Attila Makkos; Zsuzsanna Aschermann; József Janszky; Sámuel Komoly; Rita Weintraut; Kázmér Karádi; Norbert Kovács
Journal:  Parkinsons Dis       Date:  2016-05-16

8.  Minimal Clinically Important Difference on Parkinson's Disease Sleep Scale 2nd Version.

Authors:  Krisztina Horváth; Zsuzsanna Aschermann; Péter Ács; Gabriella Deli; József Janszky; Sámuel Komoly; Kázmér Karádi; Márton Kovács; Attila Makkos; Béla Faludi; Norbert Kovács
Journal:  Parkinsons Dis       Date:  2015-10-11

9.  Comparing Sensitivity and Specificity of Addenbrooke's Cognitive Examination-I, III and Mini-Addenbrooke's Cognitive Examination in Parkinson's Disease.

Authors:  Tivadar Lucza; Zsuzsanna Ascherman; Márton Kovács; Attila Makkos; Márk Harmat; Annamária Juhász; József Janszky; Sámuel Komoly; Norbert Kovács; Krisztina Dorn; Kázmér Karádi
Journal:  Behav Neurol       Date:  2018-10-02       Impact factor: 3.342

10.  The Parkinson's Disease Composite Scale Is Adequately Responsive to Acute Levodopa Challenge.

Authors:  Dávid Pintér; Pablo Martinez-Martin; József Janszky; Norbert Kovács
Journal:  Parkinsons Dis       Date:  2019-09-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.